SYNAPS Dx
PrivateLast Round
Series A
Oct 12, 2021
Total Funding Raised
$10M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
SYNAPS Dx is a diagnostics company that researches, develops, and commercializes diagnostics for neurodegenerative disorders, including its primary product DISCERN™, a minimally invasive test for the definitive diagnosis of Alzheimer's disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Telemedicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SYNAPS Dx Comparables
Compare SYNAPS Dx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CND Life Sciences | 80% | |
| C2N Diagnostics | 78% | |
| Labcorp | 72% | |
SYNAPS Dx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 12, 2021 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 2041% MoM, from 44 to 942.
- May 14, 2025
Grew 16% QoQ, from 19 to 22 employees.
SYNAPS Dx Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about SYNAPS Dx's valuation, stock price, and market status.